CGON CG Oncology, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1991792 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY183.6%
TTM net income YoY-56.8%
TTM EPS YoY-34.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-4,293.5%
Net margin-3,851.1%
FCF margin-3,068.0%
EBITDA margin-4,237.7%
Returns
ROE-28.3%
ROA-26.7%
ROIC (approx.)-26.0%
Asset turnover0.01x
Leverage & solvency
Liabilities / assets5.3%
Debt / equity0.00x
Current ratio21.70x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.79x
Accruals ratio-5.6%
Payout ratio—
Capex / revenue30.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $4.04M | $1.14M |
| R&D expense | $116.64M | $82.10M |
| SG&A expense | $73.53M | $33.70M |
| Operating income | -$190.77M | -$114.67M |
| Income tax | -$270,000 | $1,000 |
| Net income | -$161.00M | -$88.04M |
| EBITDA | -$189.33M | -$114.63M |
| EPS (basic) | -2.08 | -1.41 |
| EPS (diluted) | -2.08 | -1.41 |
| Weighted avg. shares (diluted) | 77.30M | 62.50M |
| Balance sheet | ||
| Cash & equivalents | $32.49M | $257.07M |
| Short-term investments | $709.66M | $484.93M |
| Receivables | $688,000 | $0 |
| Inventory | $1.56M | $0 |
| Current assets | $759.48M | $754.21M |
| PP&E, net | $15.60M | $272,000 |
| Goodwill | $10.30M | $0 |
| Intangibles | $575,000 | $0 |
| Total assets | $791.59M | $754.80M |
| Current liabilities | $30.84M | $21.37M |
| Long-term debt | $3.00M | $0 |
| Total debt | $3.00M | $0 |
| Total liabilities | $38.99M | $21.42M |
| Shareholders' equity | $752.60M | $733.38M |
| Net debt | -$29.49M | -$257.07M |
| Shares outstanding | 80.69M | 76.15M |
| Cash flow statement | ||
| Operating cash flow | -$132.35M | -$78.71M |
| Capital expenditure | $134,000 | $234,000 |
| Free cash flow | -$132.48M | -$78.95M |
| Investing cash flow | -$245.82M | -$300.76M |
| Financing cash flow | $153.59M | $628.28M |
| Depreciation & amortization | $1.45M | $32,000 |
| Stock-based compensation | $26.68M | $11.40M |
Free plan shows the latest 2 periods; Pro shows all 3 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.